Tarlatamab is a novel bispecific T-cell engager immunotherapy that has demonstrated efficacy against small-cell lung cancer (SCLC) in terms of noteworthy anticancer activity and survival outcomes. However, no studies have detailed the patterns of disease progr... ...

请注册登录后继续浏览